Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry
| Autor: | Ziad Reguiai, Pierre André Becherel, Jean Luc Perrot, Anne Claire Fougerousse, Edouard Begon, Claire Poreaux, Claire Boulard, Guillaume Chaby, Charlotte Fite, Inès Zaraa, Dominique Lons-Danic, Anne-Laure Liegeon, Josiane Parier, Nathalie Quiles-Tsimaratos, Laurene David, François Maccari |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Acta Dermato-Venereologica, Vol 103 (2023) |
| Druh dokumentu: | article |
| ISSN: | 0001-5555 1651-2057 |
| DOI: | 10.2340/actadv.v103.14153 |
| Popis: | The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|